Home/Editas Medicine/Gregory Whitehead
GW

Gregory Whitehead

Executive Vice President and Chief Technical and Quality Officer

Editas Medicine

Editas Medicine Pipeline

DrugIndicationPhase
EDIT-401Hyperlipidemia and Atherosclerotic Cardiovascular Disease (ASCVD)Pre-clinical
Undisclosed In Vivo ProgramSickle Cell Disease (SCD)Research
Alpha-beta T-cell medicinesOncologyUndisclosed
Gamma-delta T-cell medicinesOncologyUndisclosed